Pacer Advisors Inc. Purchases 7,956 Shares of Labcorp Holdings Inc. $LH

Pacer Advisors Inc. increased its position in Labcorp Holdings Inc. (NYSE:LH) by 2.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 313,702 shares of the medical research company’s stock after buying an additional 7,956 shares during the quarter. Pacer Advisors Inc.’s holdings in Labcorp were worth $78,702,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in Labcorp in the 4th quarter valued at approximately $1,677,000. Invesco Ltd. lifted its holdings in shares of Labcorp by 7.1% during the fourth quarter. Invesco Ltd. now owns 1,391,978 shares of the medical research company’s stock worth $349,220,000 after purchasing an additional 91,867 shares during the period. Corient Private Wealth LLC lifted its holdings in shares of Labcorp by 242.5% during the fourth quarter. Corient Private Wealth LLC now owns 92,438 shares of the medical research company’s stock worth $23,191,000 after purchasing an additional 65,451 shares during the period. Vident Advisory LLC grew its stake in shares of Labcorp by 23.9% in the fourth quarter. Vident Advisory LLC now owns 21,961 shares of the medical research company’s stock worth $5,510,000 after purchasing an additional 4,232 shares during the last quarter. Finally, Beacon Pointe Advisors LLC grew its stake in shares of Labcorp by 15.0% in the fourth quarter. Beacon Pointe Advisors LLC now owns 1,812 shares of the medical research company’s stock worth $455,000 after purchasing an additional 237 shares during the last quarter. Institutional investors own 95.94% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on LH. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Labcorp in a research report on Friday, May 8th. Piper Sandler upped their price target on Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research report on Tuesday, February 24th. Evercore restated an “outperform” rating and set a $300.00 price objective on shares of Labcorp in a research report on Wednesday, April 8th. Wall Street Zen lowered Labcorp from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Finally, Robert W. Baird set a $334.00 target price on Labcorp in a report on Friday, May 1st. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Labcorp currently has a consensus rating of “Moderate Buy” and an average target price of $308.00.

Labcorp Trading Down 1.4%

LH opened at $255.96 on Friday. Labcorp Holdings Inc. has a twelve month low of $241.81 and a twelve month high of $293.72. The company has a fifty day moving average of $261.71 and a 200-day moving average of $265.56. The stock has a market cap of $20.99 billion, a PE ratio of 22.67, a price-to-earnings-growth ratio of 1.82 and a beta of 0.90. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68.

Labcorp (NYSE:LH) last released its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.09 by $0.16. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. Labcorp’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, sell-side analysts predict that Labcorp Holdings Inc. will post 18 EPS for the current year.

Labcorp Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Friday, May 29th were paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend was Friday, May 29th. Labcorp’s payout ratio is currently 25.51%.

Insider Activity

In other Labcorp news, CEO Adam H. Schechter sold 5,903 shares of Labcorp stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $254.50, for a total value of $1,502,313.50. Following the completion of the sale, the chief executive officer directly owned 107,234 shares in the company, valued at approximately $27,291,053. The trade was a 5.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Kathryn W. Kyle sold 762 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $263.89, for a total value of $201,084.18. Following the completion of the transaction, the executive vice president directly owned 3,813 shares in the company, valued at approximately $1,006,212.57. This trade represents a 16.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.84% of the stock is owned by corporate insiders.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.